MarketInOut Stock Screener Log In | Sign Up

Arecor Therapeutics Plc

LSE • Healthcare • Biotechnology • Quote as of 10/30/2026
Arecor Therapeutics Plc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeLSE
Market Capitalization37.37 mln
Float29.13 mln
Earnings Date04/27/2027

EPS

1.00
Stretched

P / E

82.50
Speculative

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

2.03
Highly suspicious

1-Year Forecast

250.50
Transformational upside

Relative Strength

82 / 100
Strongly outperforming

Business Description

Arecor Therapeutics is a UK-based clinical-stage biotech company focused on improving existing medicines and creating new treatments for people with diabetes and other conditions. Using its proprietary Arestat platform, the company reformulates therapeutic products to make them more effective, working both independently and in partnership with other pharmaceutical firms. Its pipeline includes faster-acting and more concentrated insulin formulations, a treatment for severe low blood sugar episodes, and collaborative projects exploring oral GLP-1 therapies and insulins designed for implantable pumps.

Key Fundamentals

EPS1.00
P/E82.50
ROE-91.19
RPS0.02
ROIC-325
ROA-60.24
Interest Cover-810
EBITDA, mln-2.98
EV / EBITDA-11.49
EV / EBIT-11.11
Revenue, mln0.19
EV / Revenue177

Quote Details

Last 82.50
Change 1 (1.23%)
Open 82.50
Volume 0
Turnover 0
Average Volume 25,933

Financial Ratios

Pre-Tax Profit Margin-1,591
Leverage Ratio1.26
Current Ratio4.29
Price / Book8.42
Price / Tangible Book8.25
Debt / Equity0.02
Price / Sales165

Financial Strength

Altman Z-Score7.73
Piotroski F-Score 6 / 9
Beneish M-Score2.03
1-Year Target Price250.50

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 1.54% 78 / 100   
1 Month 13.79% 96 / 100   
2 Months 32.94% 97 / 100   
6 Months 17.86% 87 / 100   
1 Year 10% 55 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog